Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections

[1]  W. Honer,et al.  COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics , 2022, Drug Metabolism and Disposition.

[2]  B. Yeğen,et al.  Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects , 2022, Pharmaceutics.

[3]  B. Yeğen,et al.  Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis , 2022, Drug delivery.

[4]  O. Ramilo,et al.  Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. , 2022, The Lancet. Infectious diseases.

[5]  A. Mitraki,et al.  Remdesivir-loaded bis-MPA hyperbranched dendritic nanocarriers for pulmonary delivery , 2022, Journal of Drug Delivery Science and Technology.

[6]  C. Pauza,et al.  Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences , 2022, COVID.

[7]  O. Ahmed,et al.  Pulmonary Delivery of Hydroxychloroquine Nanostructured Lipid Carrier as a Potential Treatment of COVID-19 , 2022, Polymers.

[8]  Wei Chen,et al.  Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial , 2022, The Lancet Respiratory Medicine.

[9]  K. Kothapalli,et al.  Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19 , 2022, Prostaglandins, Leukotrienes and Essential Fatty Acids.

[10]  David J. Peeler,et al.  Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes , 2022, Journal of Controlled Release.

[11]  A. Iwasaki,et al.  Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccination , 2022, bioRxiv.

[12]  Wing-Hin Lee,et al.  Nanotechnology-based therapeutics for targeting inflammatory lung diseases. , 2022, Nanomedicine.

[13]  D. Brody,et al.  Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19 , 2022, mAbs.

[14]  J. Drago,et al.  Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment , 2022, International Journal of Pharmaceutics.

[15]  E. Ricci-Júnior,et al.  Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect , 2022, Journal of Nanostructure in Chemistry.

[16]  Hui-yuan Wang,et al.  Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants , 2022, Acta Pharmaceutica Sinica B.

[17]  Bao-Zhong Wang,et al.  Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice , 2022, ACS applied materials & interfaces.

[18]  Zhenguo Chen,et al.  Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody , 2021, Cell.

[19]  M. El-Kemary,et al.  Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment , 2021, International Journal of Biological Macromolecules.

[20]  H. K. Chaudhari,et al.  Niclosamide & challenges in chemical modifications: A broad review on enhancement of solubility , 2021, Journal of the Indian Chemical Society.

[21]  S. Béni,et al.  Molecular interactions in remdesivir-cyclodextrin systems , 2021, Journal of Pharmaceutical and Biomedical Analysis.

[22]  B. Igyártó,et al.  The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, iScience.

[23]  N. Mignet,et al.  Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses , 2021, PPAR research.

[24]  M. Farzan,et al.  Mechanisms of SARS-CoV-2 entry into cells , 2021, Nature reviews. Molecular cell biology.

[25]  Alaa S. Tulbah,et al.  Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs) , 2021, Pharmaceuticals.

[26]  Di Wu,et al.  Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19 , 2021, Asian Journal of Pharmaceutical Sciences.

[27]  W. Cui,et al.  Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm , 2021, Matter.

[28]  A. Shamloo,et al.  Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion , 2021, International Journal of Pharmaceutics.

[29]  James E. Dahlman,et al.  Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs , 2021, Nature Biomedical Engineering.

[30]  H. Chan,et al.  Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19 , 2021, Pharmaceutics.

[31]  Jordan J. Clark,et al.  A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 , 2021, Nature Communications.

[32]  Y. Roh,et al.  RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform. , 2021, Nanomedicine : nanotechnology, biology, and medicine.

[33]  Xiaohong Song,et al.  Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial , 2021, The Lancet Infectious Diseases.

[34]  Ya Gao,et al.  Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019 , 2021, EClinicalMedicine.

[35]  Kristen D. Popowski,et al.  Cell-Mimicking Nanodecoys Neutralize SARS-CoV-2 and Mitigate Lung Injury in a Nonhuman Primate Model of COVID-19 , 2021, Nature Nanotechnology.

[36]  A. Oomens,et al.  Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. , 2021, Vaccine.

[37]  J. Chan,et al.  Inhaled Dry Powder Formulation of Tamibarotene, a Broad‐Spectrum Antiviral against Respiratory Viruses Including SARS‐CoV‐2 and Influenza Virus , 2021, Advanced Therapeutics.

[38]  M. Jenkins,et al.  Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge , 2021, Journal of virology.

[39]  Weiqi Wang,et al.  Antiviral and Anti‐Inflammatory Treatment with Multifunctional Alveolar Macrophage‐Like Nanoparticles in a Surrogate Mouse Model of COVID‐19 , 2021, Advanced Science.

[40]  Miguel O. Jara,et al.  Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters , 2021, International Journal of Pharmaceutics.

[41]  R. Compans,et al.  Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains , 2021, Proceedings of the National Academy of Sciences.

[42]  W. P. Duprex,et al.  Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses , 2021, Science Advances.

[43]  N. Petrovsky,et al.  Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets , 2021, npj Vaccines.

[44]  B. Igyártó,et al.  The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, bioRxiv.

[45]  N. Kunda,et al.  Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro , 2021, Nanomedicine.

[46]  R. Valenta,et al.  Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation , 2021, Allergy.

[47]  G. Randall,et al.  Nanotraps for the containment and clearance of SARS-CoV-2 , 2021, bioRxiv.

[48]  C. Evans,et al.  Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury , 2021, Frontiers in Pharmacology.

[49]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[50]  R. Williams,et al.  In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters , 2020, bioRxiv.

[51]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[52]  H. Kerstjens,et al.  Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers , 2020, medRxiv.

[53]  H. Steckel,et al.  Development of High Dose Oseltamivir Phosphate Dry Powder for Inhalation Therapy in Viral Pneumonia , 2020, Pharmaceutics.

[54]  M. Lanari,et al.  Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines , 2020, Vaccines.

[55]  H. Chan,et al.  Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. , 2020, Journal of aerosol medicine and pulmonary drug delivery.

[56]  N. Krogan,et al.  An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike , 2020, Science.

[57]  Yee-Chun Chen,et al.  A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study , 2020, Clinical and translational science.

[58]  R. Jordan,et al.  Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases , 2020, Proceedings of the National Academy of Sciences.

[59]  F. Martinón-Torres,et al.  Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. , 2020, The Lancet. Respiratory medicine.

[60]  Yakun Wan,et al.  A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential , 2020, bioRxiv.

[61]  H. Harapan,et al.  Remdesivir and its antiviral activity against COVID-19: A systematic review , 2020, Clinical Epidemiology and Global Health.

[62]  D. Bernstein,et al.  Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults , 2020, Human vaccines & immunotherapeutics.

[63]  L. Avery,et al.  The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review , 2020, Hospital pharmacy.

[64]  R. Williams,et al.  Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing , 2020, bioRxiv.

[65]  M. Madou,et al.  Nanotechnology for COVID-19: Therapeutics and Vaccine Research , 2020, ACS nano.

[66]  R. Fassihi,et al.  Novel approach for low‐dose pulmonary delivery of hydroxychloroquine in COVID‐19 , 2020, British journal of pharmacology.

[67]  J. Wedzicha,et al.  Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon , 2020, bioRxiv.

[68]  V. Pokharkar,et al.  Development of sustained release Oseltamivir phosphate dry powder inhaler: In-vitro and in-vivo Toxicological Studies. , 2020, Current drug delivery.

[69]  C. Bachert,et al.  mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice , 2020, Molecular therapy. Nucleic acids.

[70]  Michael A. Spinelli,et al.  The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin , 2020, Nature Medicine.

[71]  Arzu Ari.  Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19 , 2020, Respiratory Medicine.

[72]  F. Buckner,et al.  Hydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection , 2020, Clinical and translational science.

[73]  A. Klimke,et al.  Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection , 2020, Medical Hypotheses.

[74]  Mahmoud Kandeel,et al.  Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease , 2020, Life Sciences.

[75]  I. A. Hajam,et al.  Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens , 2020, Veterinary Research.

[76]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[77]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[78]  P. Kwong,et al.  Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates , 2020, PloS one.

[79]  R. Karron,et al.  Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with SH non-coding region is highly immunogenic in children. , 2020, The Journal of infectious diseases.

[80]  E. Barr,et al.  Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children , 2020 .

[81]  R. Karron,et al.  Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. , 2019, The Journal of infectious diseases.

[82]  R. Karron,et al.  Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children , 2019, The Journal of infectious diseases.

[83]  A. Nicosia,et al.  Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults , 2019, Journal of Infection.

[84]  W. Hinrichs,et al.  Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge , 2018, European Journal of Pharmaceutics and Biopharmaceutics.

[85]  R. Chemaly,et al.  Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  Bao-Zhong Wang,et al.  Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[87]  M. Ackermann,et al.  Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs , 2018, mAbs.

[88]  Fangjia Lu,et al.  Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs , 2018, Front. Immunol..

[89]  R. Karron,et al.  Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children , 2018, The Journal of infectious diseases.

[90]  R. Karron,et al.  Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children , 2018, The Journal of infectious diseases.

[91]  S. Doernberg,et al.  Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single‐center retrospective cohort study and review of the literature , 2018, Transplant infectious disease : an official journal of the Transplantation Society.

[92]  Dia Ndongo,et al.  Viral and Bacterial Etiologies of Acute Respiratory Infections Among Children Under 5 Years in Senegal , 2018, Microbiology insights.

[93]  W. Hinrichs,et al.  Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus , 2018, Drug delivery.

[94]  A. Abdoli,et al.  Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA , 2018, Drug Delivery and Translational Research.

[95]  G. Ippolito,et al.  QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient , 2017, PLoS neglected tropical diseases.

[96]  V. Gerdts,et al.  Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus , 2017, Human vaccines & immunotherapeutics.

[97]  Tianfeng Chen,et al.  Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus , 2017, International journal of nanomedicine.

[98]  R. Klopfleisch,et al.  Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation , 2017, Nanomedicine: Nanotechnology, Biology and Medicine.

[99]  Jingdong Song,et al.  A single intranasal administration of virus‐like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus , 2017, Antiviral research.

[100]  Yu Xia,et al.  Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with zanamivir through p38 and JNK signaling pathways , 2017 .

[101]  Bao-Zhong Wang,et al.  Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro , 2017, International journal of nanomedicine.

[102]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[103]  William A. Lee,et al.  Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses , 2017, Journal of medicinal chemistry.

[104]  Y. Tong,et al.  Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice , 2017, Acta biochimica et biophysica Sinica.

[105]  S. van Drunen Littel-van den Hurk,et al.  A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. , 2016, Virology.

[106]  M. Kanekiyo,et al.  Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus , 2016, Scientific Reports.

[107]  J. Polli,et al.  Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin , 2016, Journal of Pharmaceutical Sciences.

[108]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[109]  C. Russell,et al.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses , 2016, Expert review of vaccines.

[110]  B. Bettencourt,et al.  ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[111]  R. Karron,et al.  A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children , 2015, Science Translational Medicine.

[112]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[113]  J. Baker,et al.  Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats , 2015, Human vaccines & immunotherapeutics.

[114]  Andrew J. Pollard,et al.  Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults , 2015, Science Translational Medicine.

[115]  Jianping Liu,et al.  Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation , 2015, Drug delivery.

[116]  A. Freifeld,et al.  Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation , 2015, Current Infectious Disease Reports.

[117]  H. Gill,et al.  M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection. , 2015, Vaccine.

[118]  D. Meyerholz,et al.  RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets , 2015, PLoS pathogens.

[119]  Wei Xu,et al.  Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection , 2015, Viruses.

[120]  P. Dormitzer,et al.  Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. , 2014, Vaccine.

[121]  Harvinder S Gill,et al.  Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. , 2014, Nanomedicine.

[122]  W. Hinrichs,et al.  Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[123]  K. Yamanishi,et al.  Chitosan Nanoparticle Encapsulated Hemagglutinin-Split Influenza Virus Mucosal Vaccine , 2014, AAPS PharmSciTech.

[124]  B. Haijema,et al.  Bacterium-Like Particles for Efficient Immune Stimulation of Existing Vaccines and New Subunit Vaccines in Mucosal Applications , 2013, Front. Immunol..

[125]  E. Stillman,et al.  Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells. , 2013, Vaccine.

[126]  U. Popat,et al.  Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. , 2013, The Journal of antimicrobial chemotherapy.

[127]  J. Buer,et al.  Immunization with Biodegradable Nanoparticles Efficiently Induces Cellular Immunity and Protects against Influenza Virus Infection , 2013, The Journal of Immunology.

[128]  B. Salzberger,et al.  Aerosolized ribavirin for patients with cancer and respiratory syncytial virus infection. , 2013, The Journal of infectious diseases.

[129]  M. Munsell,et al.  An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. , 2012, The Journal of infectious diseases.

[130]  J. Falloon,et al.  Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children , 2012, The Pediatric infectious disease journal.

[131]  R. Rudraraju,et al.  Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. , 2012, Vaccine.

[132]  J. Baker,et al.  A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease , 2011, PloS one.

[133]  Wouter L J Hinrichs,et al.  Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. , 2011, Vaccine.

[134]  R. Chemaly,et al.  Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. , 2011, Blood.

[135]  M. Zamora,et al.  RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. , 2011, American journal of respiratory and critical care medicine.

[136]  G. Losonsky,et al.  PHASE-I STUDY MEDI-534, OF A LIVE, ATTENUATED INTRANASAL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA-3 VIRUS IN SEROPOSITIVE CHILDREN , 2009, The Pediatric infectious disease journal.

[137]  A. Molla,et al.  Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir. , 2009, Journal of medicinal chemistry.

[138]  S. Elbashir,et al.  Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). , 2008, Antiviral research.

[139]  W. Hinrichs,et al.  Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. , 2007, Vaccine.

[140]  E. Simões,et al.  Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. , 2007, The Journal of pediatrics.

[141]  D A Groneberg,et al.  Fundamentals of pulmonary drug delivery. , 2003, Respiratory medicine.

[142]  A. A. Haller,et al.  Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine Vector , 2000, Journal of Virology.